Prognostic and Demographic Characteristics of Acute Myelogenous Leukemia Patients: a Five-Year Study in Mashhad, Iran
Abstract
Background: Acute myeloid leukemia (AML) is a disease in elderly patients, with a mean age of diagnosis of 70 years. We have analyzed the clinicopathology features and experimental variables in AML patients in Eastern Iran and the correlation between survival and FAB subgroups of AML. Materials and Methods: During 2009 to 2014 in a retrospective study, 98 patients with AML referred to the Clinic of Hematology. More of patients had just chemotherapy regimen of “7+3” and none of the patients had radiotherapy. Also, one-third patients had bone marrow transplantation. The mean follow-up was 40 months and at this time, there were 58 deaths. Results: The mean age of the patients at diagnosis was 40.6±15.4 years (range, 17-77 years) that 40 patients (40.4%) were male. AML-M5 and M3 were the most subgroups in patients with 29.5% and 26.1%, respectively. Twenty patients (20.4%) had lymphadenopathy. Weakness and lethargy were the most complaints. 5-year survival rate was 39.6% and mean survival was 27.3 months. Prevalence of females was more in AML-M5 and M3 compared to other subgroups. Conclusions: The mean age in Iran and probably Middle East are lower than a lot of countries and also the percentage of females was more in our study compared with a lot of previous studies. OS in our patients is higher than other studies that should be notice to chemotherapy regimen, radiotherapy and bone marrow transplantation in patients in future studies. Prevalence of AML-M5 in our study is higher than other studies.Ghanavat M, Pedram M, Keikhaie B, Jaseb K, Ansari N. Immunophenotyping Results from Flow Cytometric Analysis of Children with Acute Leukemia in Ahwaz Province. Basic & Clinical Cancer Research. 2014;6:2-6.
Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37:649-58.
Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2011;2:95-107.
Ghadiany M, Rahimi H, Rezvani H, Mohammad Alizadeh A, Zamani N, Mehdizadeh M, et al. Prophylaxis of neutropenic fever with ciprofloxacin in patients with acute myeloid leukemia treated with intensive chemotherapy. Asia Pac J Clin Oncol. 2016;12:e11-5.
Shah BK, Ghimire KB. Improved survival among older acute myeloid leukemia patients - a population-based study. Acta Oncol. 2014;53:935-8.
Douer D. The epidemiology of acute promyelocytic leukemia. Best Practice & Reasearch Clinical Haematology.2003;16:357-67.
Ziaei JE. High frequency of acute promyelocytic leukemia in northwest Iran. Asian Pac J Cancer Prev.2004;5:188-9.
Harani MS, Adil SN, Shaikh MU, Kakepoto GN, Khurshid M. Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. J Ayub Med Coll Abbottabad.2005;17:26-9.
Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916-24.
Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, et al. Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori. 2009;95:303-10.
Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol. 2012;96:186-93.
Enjeti AK, Tien SL, Sivaswaren CR. Cytogenetic abnormalities in de novo acute myeloid leukemia in adults: relation to morphology, age, sex and ethnicity - a single center study from Singapore. Hematol J. 2004;5:419-25.
Byrd JC, Lawrence D, Arthur DC, Pettenati MJ, Tantravahi R, Qumsiyeh M, et al. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res.1998;4:1235-41.
Harani MS, Adil SN, Shaikh MU, Kakepoto GN, Khurshid M. Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. J Ayub Med Coll Abbottabad. 2005;17:26-9.
Ashrafi F, Shahnazari R, Samimi MA, Mehrzad V. Results of treatment of acute myeloid leukemia in central part of Iran. Adv Biomed Res.2013;2:51.
Ayremlou P, Razavi SM, Solaymani-Dodaran M, Vakili M, Asadi-Lari M. Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011). Iran J Cancer Prev.2012;5:157-63.
Sepehrizadeh Z, Mohammadi M, Emami A, Yazdi MT, Bozchlou SH, Khorramizadeh MR, et al. Assessment of cytokine expression profile in acute myeloid leukemia patients before and after chemotherapy. Turk J Haematol.2014;31:149-54.
Alibhai SM, Leach M, Minden MD, Brandwein J. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer. 2009;115:2903-11.
Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, et al. Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori. 2009;95:303-10.
Iwakiri R, Ohta M, Mikoshiba M, Tsutsumi H, Kumakawa T, Mori M. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases. Int J Hematol. 2002;75:45-50.
Sazawal S, Kumar B, Hasan SK, Dutta P, Kumar R, Chaubey R, et al. Haematological & molecular profile of acute myelogenous leukaemia in India. Indian J Med Res. 2009;129:256-61.
Hassan K, Qureshi M, Shafi S, Ikram N, Akhtar MJ. Acute myeloid leukemia-FAB classification and its correlation with clinico-haematological features. J Pak Med Assoc. 1993;43:200-3.
Greinix HT, Keil F, Brugger SA, Reiter E, Linkesch W, Lechner K, et al. Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. Ann Hematol. 1996;72:53-9.
Padilha SL, Souza EJ, Matos MC, Domino NR. Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná. Rev Bras Hematol Hemoter. 2015;37:21-7.
| Files | ||
| Issue | Vol 8 No 4 (2016) | |
| Section | Original Articles | |
| Keywords | ||
| Acute myeloid leukemia Survival Age FAB subgroups | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
